At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 183 enrolled
Drug / intervention
MEK162drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II, Open-label Study to Assess the Safety and Efficacy of Oral MEK162 in Adults With Locally Advanced and Unresectable or Metastatic Malignant Cutaneous Melanoma, Harboring BRAFV600 or NRAS Mutations
In Brief
A Phase 2 clinical trial evaluating MEK162 for BRAF or NRAS Mutant Metastatic Melanoma. Completed, enrolled 183 participants across 25 sites in 5 countries.
Detailed Summary
The study will assess the safety and efficacy of single-agent MEK162 in adult patients with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600E or NRAS mutations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBRAF or NRAS Mutant Metastatic Melanoma
CountriesGermany, Italy, Netherlands, Switzerland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2011
Enrollment StartMar 2011
Primary CompletionJan 2014
Study CompletionFeb 2023
TodayJul 2026
First PostedMar 22, 2011
Enrollment StartMar 24, 2011
Primary CompletionJan 7, 2014
Study CompletionFeb 6, 2023
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 15.3 years ago
Interventions
MEK162drug